BioVie invited to present bezisterim data at NIH's RECOVER-TLC Long COVID workshop

BioVie announced it has been invited to present data on its investigational oral therapy bezisterim at the 2026 RECOVER-Treating Long COVID (RECOVER-TLC) Hybrid Workshop, hosted by NIAID and the Foundation for the NIH. The invitation follows the company's recent reporting of trial results from its ADDRESS-LC Long COVID and SUNRISE-PD Parkinson's studies.

Detected & updated continuously · Source: Nebula